Swapping just an hour of TV a day for something more active could significantly lower the risk of developing major depression—especially in middle age. A large Dutch study tracking more than 65,000 adults over four years found that replacing 60 minutes of TV with other activities cut depression risk by 11% overall, and by nearly 19% in middle-aged adults. The more time people reallocated—up to two hours—the greater the benefit, with risk dropping as much as 43% in midlife.

A six-week study from the University of Nottingham suggests that pairing fermented kefir with a diverse prebiotic fiber mix may deliver a powerful anti-inflammatory boost. This “synbiotic” combination outperformed omega-3 supplements and fiber alone, leading to the broadest drop in inflammation-related proteins in healthy adults. By feeding beneficial microbes and helping them produce compounds like butyrate, the combo appeared to improve overall immune balance and metabolic health.

A simple brain-training program that sharpens how quickly older adults process visual information may have a surprisingly powerful long-term payoff. In a major 20-year study of adults 65 and older, those who completed five to six weeks of adaptive “speed of processing” training — along with a few booster sessions — were significantly less likely to develop dementia, including Alzheimer’s disease, even two decades later. Participants who received the boosted speed training had a 25% lower dementia risk compared to those who received no training, making it the only intervention in the trial to show such a lasting protective effect.

A new clinical trial suggests that changing when you eat could make a meaningful difference for people living with Crohn’s disease. Researchers found that time-restricted feeding, a form of intermittent fasting that limits meals to an 8-hour daily window, reduced disease activity by 40% and cut abdominal discomfort in half over 12 weeks. Participants also lost weight and showed healthier inflammation and immune markers, even though they did not reduce calories or change what they ate.

Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide (Victoza and Saxenda) can lead to substantial weight loss in people with obesity. But while the results are impressive, researchers caution that most trials were funded by drugmakers, long term safety data are still limited, and side effects such as nausea are common.